PDCD1 and neoplasm: Antibodies against programmed cell death protein 1 (PD-1)/PD ligand 1 (PD-L1) prevent PD-1/PD-L1 interactions between tumour and immune cells, which renders the tumour susceptible to immune cell–mediated attack.